NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Law & Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law & Health Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Braintree Laboratories, Inc.



Braintree Laboratories in-licenses rights to chemoprevention agent against colorectal cancer



April 8th, 2006

Braintree Laboratories, Inc., has in-licensed the global rights to develop and commercialize BLI-600, a patent protected compound that has shown significant promise as a chemoprevention agent, from INRA Transfert (IT), a subsidiary of National Institute for Agricultural Research (INRA), Paris, France.

Under the terms of the agreement, Braintree Laboratories is responsible for the clinical development and worldwide registration of the compound for chemoprevention and/or treatment of colorectal cancer.

The Foods & Cancer team of the joint research group ENVT-INRA Xenobiotics managed by Pr Denis Corpet, leader in the field of food and colon...


Source: Law & Health Weekly (2006-04-08)

NewsRx Passes
Advertisement
More Articles

------------------------
Security by Verisign PR Login